Ballard Power Systems has received a second order for 15 megawatts (MW) of fuel cell systems for stationary applications from an unnamed customer specializing in renewable off-grid power generation. The order includes 150 FCmove®-HD+ 100 kW fuel cell modules, with deliveries expected to begin in the second half of 2026. These systems will be used in hydrogen gensets for various applications such as live events, construction, movie sets, and critical infrastructure, highlighting the growing adoption of zero-emission fuel cell solutions.

Ballard Power Systems announced a 15 MW order for FCmove®-HD+ fuel cell systems, comprising 150 individual 100 kW modules, for stationary off-grid power applications. This marks the second similar-scale order from the same renewable energy customer, with deliveries expected to commence in the second half of 2026. These hydrogen gensets will be utilized across various applications including live events, construction, film sets, critical infrastructure, and EV charging, offering a zero-emission, low-noise alternative to traditional diesel generation.

Alithea Genomics has partnered with Revvity Inc. to broaden the availability of its MERCURIUS DRUG-seq and MERCURIUS Total DRUG-seq platforms globally. This collaboration integrates Alithea Genomics' scalable RNA sequencing technologies with Revvity’s drug discovery and screening solutions, offering researchers enhanced capabilities for high-throughput transcriptomic profiling. The partnership aims to accelerate drug development by facilitating the seamless incorporation of transcriptomics into various screening, functional genomics, and AI-driven discovery workflows.

T-Mobile US, Inc. (NASDAQ:TMUS) has announced a cash dividend of $1.02 per share, payable on September 10, 2026, to stockholders of record as of August 28, 2026. This marks the company's third consecutive year of dividend increases, with a nearly 16% growth over the past year and a current dividend yield of 2.16%. The company, with a $204 billion market capitalization, also recently introduced an AI-powered network optimization tool and joined a cybersecurity information-sharing center.

Netflix is developing a series adaptation of Hannah Grace's popular hockey romance novel, "Icebreaker." The story features an aspiring Olympic figure skater who must share a rink with an NHL prospect. Amanda Lasher will serve as showrunner and co-write the series, which is being produced by Alex Cooper's Unwell Productions.

A10 Networks (ATEN) has acquired TrojAI to strengthen its sovereign AI security solutions, a move aimed at protecting AI models and data for its clients. While this acquisition is not expected to significantly impact fiscal year 2026 financials, it positions A10 for growth in secure AI deployments over the next 2-5 years. Despite a strong GF Score of 81 indicating potential for long-term returns, investors should be cautious due to ATEN's high P/E ratio and recent insider selling activity.

Dorothy D. Hayes, a director at BigBear.ai (NYSE: BBAI), was granted 36,070 restricted stock units (RSUs) on June 14, 2026. These RSUs, each representing one share of Common Stock, will vest on June 14, 2027, provided her service continues. Following this award, her direct holdings in the company amount to 240,220 shares.

Mission Produce director Jay A. Pack purchased 37,450 shares of the company's common stock for $413,195 on June 11, 2026, with prices ranging from $11.03 to $11.04 per share. The purchases were made both directly by Mr. Pack and indirectly by his spouse. Following these transactions, Mr. Pack's total direct and indirect holdings in Mission Produce stock amount to a significant number of shares, indicating his continued investment in the company, despite recent challenges including lower-than-expected Q2 earnings due to avocado pricing and fruit size issues.

Baird has maintained a Neutral rating on Braemar Hotels & Resorts (BHR) while significantly lowering its price target from $3.50 to $2.00. Despite this, GuruFocus indicates BHR is approximately 3.6% undervalued with a GF Value™ of $2.22 against a current trading price of $2.14. The company's GF Score™ of 60 reflects moderate performance, with concerns remaining around its financial strength and growth potential.

AstraZeneca's Truqap (capivasertib) has received FDA approval for an expanded prostate cancer indication, making it the first AKT inhibitor approved in a second tumor type. The approval is for its use in combination with J&J’s Zytiga and prednisone for PTEN-deficient mAPMN/S prostate cancer, based on positive data from the CAPItello-281 study. This expansion is expected to further drive Truqap sales, which already saw a 47% increase in Q1 2026.